Novartis AG annual revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Novartis AG Revenue Growth & History (NVS)
Novartis AG reported $54.53B in revenue for fiscal 2025, an increase of 8.38% from the previous fiscal year.
View full Novartis AG company overviewNovartis AG annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $54.53B | $4.21B | +8.38% |
| 2024 | 2024-12-31 | $50.32B | $4.88B | +10.73% |
| 2023 | 2023-12-31 | $45.44B | $3.23B | +7.66% |
| 2022 | 2022-12-31 | $42.21B | −$575.0M | −1.34% |
| 2021 | 2021-12-31 | $42.78B | −$5.88B | −12.08% |
| 2020 | 2020-12-31 | $48.66B | $1.16B | +2.44% |
| 2019 | 2019-12-31 | $47.50B | $2.67B | +5.94% |
| 2018 | 2018-12-31 | $44.83B | $2.45B | +5.79% |
| 2017 | 2017-12-31 | $42.38B | −$6.14B | −12.65% |
| 2016 | 2016-12-31 | $48.52B | — | — |
Novartis AG quarterly revenue
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
Q2.23
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $14.95B | $897.0M | +6.38% |
| Q1 2026 | 2026-03-31 | $13.52B | — | — |
| Q4 2025 | 2025-12-31 | $13.86B | — | — |
| Q3 2025 | 2025-09-30 | $14.36B | — | — |
| Q2 2025 | 2025-06-30 | $14.05B | $1.54B | +12.32% |
| Q2 2024 | 2024-06-30 | $12.51B | $1.07B | +9.40% |
| Q2 2023 | 2023-06-30 | $11.44B | −$1.34B | −10.52% |
| Q2 2022 | 2022-06-30 | $12.78B | −$175.0M | −1.35% |
| Q2 2021 | 2021-06-30 | $12.96B | $1.61B | +14.18% |
| Q2 2020 | 2020-06-30 | $11.35B | −$417.0M | −3.54% |
| Q2 2019 | 2019-06-30 | $11.76B | $405.0M | +3.57% |
| Q2 2018 | 2018-06-30 | $11.36B | −$883.0M | −7.21% |
| Q2 2017 | 2017-06-30 | $12.24B | — | — |
Novartis AG revenue growth trends
Over the last five reported fiscal years, revenue grew from $48.66B to $54.53B, a compound annual growth rate of 2.31%. Novartis AG's latest reported quarter, Q2 2026, generated $14.95B in revenue, an increase of 6.38% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Novartis AG source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...
